Detailing the ongoing shift toward universal and next-generation vaccines designed to provide broader, more durable protection against highly mutable viruses like influenza and SARS-CoV-2. According to a World Health Organization (WHO) assessment, these innovative platforms could prevent billions of infections and save millions of lives by 2050 while simultaneously curbing antimicrobial resistance. Clinical progress is highlighted through various candidates, including Moderna’s mRNA-1010, which has reached marketing authorization filings, and Osivax’s OVX836, which recently completed enrollment for large-scale efficacy trials. Researchers are utilizing advanced technologies such as self-assembling nanoparticles and computational epitope-focusing to target stable, internal viral components that do not mutate as rapidly as surface proteins. Further ...